Stargardt Disease Clinical Trial
— GARDianOfficial title:
A Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for STARGARDT DISEASE
This is a Phase 1/2 Study to Assess the Safety and Efficacy of OCU410ST for Stargardt Disease. This is a multicenter study, which will be conducted in two phases and will enroll up to a total of 42 subjects.
Status | Recruiting |
Enrollment | 42 |
Est. completion date | October 28, 2025 |
Est. primary completion date | October 28, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 6 Years to 65 Years |
Eligibility | Inclusion Criteria: 1. Are aged 18-65. 2. Have clinical evidence of a macular lesion phenotypically consistent with Stargardt Disease 3. The study eye should have at least one well-demarcated area of atrophy with a minimum diameter of 300 microns, and total lesion size <= 18 mmE2 and a BCVA of 50 ETDRS letters or better 4. Have confirmed presence of two pathogenic mutations in the ABCA4 gene 5. Have detectable outer nuclear layer (ONL) in the macular region tomography (SD-OCT). 6. Have BCVA of 50 letters or less (using ETDRS chart) Key Inclusion Criteria for Pediatric Subjects: 1. Are aged 6-17. 2. Have clinical diagnosis of Stargardt Disease 3. The designated primary study eye must have at least one well-demarcated area of atrophy with a minimum diameter of 300 microns and a total lesion area <= 18 mmE2 and a BCVA of 35 ETDRS letters or better. 4. Have two (2) pathogenic mutations confirmed present, in the ABCA4 gene. Key Exclusion Criteria for Adult Subjects: 1. Have previous treatment with a gene therapy or cell therapy product. 2. Have any concurrent retroviral therapy that would inactivate the investigational product. 3. Have any contradictions for subretinal injection and the use of anesthesia. 4. Have genes that mimic Stargardt Disease like ELOVL4, or PROM1. Exclusion Criteria for Pediatric Subjects: 1. Have previous treatment with a gene therapy or cell therapy product. 2. Have any concurrent retroviral therapy that would inactivate the investigational product. 3. Have any intraocular surgery (including lens replacement surgery) within 6 months (prior to Screening), and any ophthalmic condition that may require surgery during the study period. 4. Have genes that mimic Stargardt Disease like ELOVL4, or PROM1. |
Country | Name | City | State |
---|---|---|---|
United States | Retina Consultants of Texas | Bellaire | Texas |
United States | Retina Foundation of the Southwest | Dallas | Texas |
United States | Duke Eye Center | Durham | North Carolina |
United States | Mississippi Retina Associates | Jackson | Mississippi |
United States | Bascom Palmer Eye Institute | Miami | Florida |
United States | Associated Retina Consultants | Phoenix | Arizona |
Lead Sponsor | Collaborator |
---|---|
Ocugen |
United States,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Other | Changes in macular thickness on Spectra Domain Optical Coherence Tomography (SD-OCT) | The change in the macular thickness will be Measured by spectral domain optical coherence tomography (SD-OCT) | 12 months (Screening to 12 months post OCU410ST administration) | |
Other | Change in Quality-of-life measure using NEI VFQ-25 (Adult subjects only) | The National Eye Institute Visual Function Questionnaire 25 (NEI-VFQ25) questionnaires will be administered to assess the impact of vision on quality of subject's life. | 12 months (Screening to 12 months post OCU410ST administration) | |
Primary | Safety (Participants With Ocular and Non-ocular AEs (Adverse Events) and SAEs (Serious Adverse Events)) | The primary endpoint is safety, determined by the number of ocular and non-ocular Study Drug-related adverse events (SDAE), treatment-emergent adverse events (TEAEs) and serious adverse events (SAEs). | 12 months (Screening to 12 months post OCU410ST administration) | |
Primary | Ophthalmic Safety: Change From Baseline in BCVA (Best Corrected Visual Acuity) | Visual function of the study eye was assessed using the Early Treatment Diabetic Retinopathy Study (ETDRS) Best Corrected Visual Acuity (BCVA) letter score. A higher score represents better vision. | 12 months (Screening to 12 months post OCU410ST administration) | |
Primary | Ophthalmic Safety: Ophthalmoscope Measurements | We will use Slit-lamp Biomicroscopy to visualize the anatomy of ocular structures before and after sub-retinal injections and follow-up visits. | 12 months (Screening to 12 months post OCU410ST administration) | |
Primary | Ophthalmic Safety: Change in the Intraocular Pressure (mmHg) | Measured by applanation or rebound tonometry with confirmation with Goldmann tonometer if IOP is outside normal range (8-21mmHg). | 12 months (Screening to 12 months post OCU410ST administration) | |
Primary | Change Using Qualitative and quantitative assessments of autofluorescence pattern (FAF) | Changes in the intensity of FAF will be evaluated from the baseline measurements, to assess the loss of retinal layers. | 12 months (Screening to 12 months post OCU410ST administration) | |
Primary | Ophthalmic Safety: Changes in Full Field ERG | The International Society for Clinical Electrophysiology of Vision (ISCEV) guidelines will be followed for conducting ff-ERG (Full-field Electroretinography) | 12 months (Screening to 12 months post OCU410ST administration) | |
Secondary | Humoral and cellular immune response | Blood samples will be collected for the assessment. The secondary safety endpoints include change from baseline in Humoral and cellular immune response in response to OCU410ST administration | 12 months (Screening to 12 months post OCU410ST administration) | |
Secondary | Shedding of Viral Vector | Blood samples will be collected for the assessment to determine AAV vector shedding in systemic circulation after OCU410ST administration | 12 months (Screening to 12 months post OCU410ST administration) | |
Secondary | Change in laboratory parameters for Hematology | Blood samples will be collected to determine any significant change in hematology parameters including hematocrit, hemoglobin, red and white blood cell count, and any other parameters deemed necessary by study investigator from baseline after OCU410ST administration. | 12 months (Screening to 12 months post OCU410ST administration) | |
Secondary | Change in laboratory parameters for Serum Chemistry | Blood samples will be collected to determine any significant change in serum chemistry parameters including electrolytes, renal functions, liver functions, comprehensive metabolic panel and any other parameters deemed necessary by study investigator from baseline after OCU410ST administration. | 12 months (Screening to 12 months post OCU410ST administration) |
Status | Clinical Trial | Phase | |
---|---|---|---|
Terminated |
NCT01676766 -
Novel Quantification Methods for Fluorescence to Detect Progression in Stargardt Disease
|
N/A | |
Enrolling by invitation |
NCT06048185 -
Non-interventional Long Term Follow-up Study of Participants Previously Enrolled in the STARLIGHT Study
|
||
Recruiting |
NCT04545736 -
Oral Metformin for Treatment of ABCA4 Retinopathy
|
Phase 1/Phase 2 | |
Recruiting |
NCT05674058 -
Function and Imaging Assessments for G1961E-associated Stargardt Disease
|
||
Recruiting |
NCT06435000 -
An Observational Study in Subjects to Follow the Progression of Stargardt Disease Type 1 (STGD1) Caused by Bi-Allelic Autosomal Recessive Mutations in the ABCA4 Gene
|
||
Completed |
NCT04909398 -
Pupil Dynamics and Color Vision for the Detection of Eye Diseases
|
N/A | |
Completed |
NCT02255981 -
Efficacy of Acupuncture in Macular Diseases
|
N/A | |
Completed |
NCT05266014 -
This is a Dose-finding Study Followed by 2-year Extension Study to Evaluate Safety and Tolerability of Tinlarebant in Adolescent Subjects With Stargardt Disease
|
Phase 1/Phase 2 | |
Recruiting |
NCT06467344 -
Study to Evaluate ACDN-01 in ABCA4-related Retinopathy (STELLAR)
|
Phase 1/Phase 2 | |
Recruiting |
NCT02435940 -
Inherited Retinal Degenerative Disease Registry
|
||
Recruiting |
NCT06445322 -
Prescreening Study to Identify Potential Participants for ACDN-01 Clinical Trials
|
||
Completed |
NCT05417126 -
Safety and Effects of a Single Intravitreal Injection of vMCO-010 Optogenetic Therapy in Subjects With Stargardt Disease
|
Phase 2 | |
Completed |
NCT03772665 -
Safety and Efficacy of Emixustat in Stargardt Disease
|
Phase 3 | |
Terminated |
NCT02875704 -
Oxidative Stress In Stargardt Disease, Age Related Macular Degeneration and Diabetic Retinopathy
|
||
Completed |
NCT03033108 -
Pharmacodynamic Study of Emixustat Hydrochloride in Subjects With Macular Atrophy Secondary to Stargardt Disease
|
Phase 2 | |
Recruiting |
NCT03011541 -
Stem Cell Ophthalmology Treatment Study II
|
N/A | |
Completed |
NCT02410122 -
The Natural History of the Progression of Atrophy Secondary to Stargardt Disease Type 4: PROM1-Related Macular Dystrophy
|
||
Enrolling by invitation |
NCT04239625 -
Open-Label Extension: Tolerability and Effects of ALK-001 on Stargardt Disease (TEASE)
|
Phase 2 | |
Recruiting |
NCT02402660 -
Phase 2 Tolerability and Effects of ALK-001 on Stargardt Disease
|
Phase 2 | |
Completed |
NCT01977846 -
A Natural History of the Progression of Stargardt Disease: Retrospective and Prospective Studies
|